Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 3,870,000 shares, a decrease of 17.0% from the December 31st total of 4,660,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is currently 2.3 days.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Thursday, December 12th. HC Wainwright raised their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. B. Riley reissued a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Stock Up 1.0 %

TRVI traded up $0.04 during trading hours on Friday, reaching $3.94. 383,085 shares of the company’s stock traded hands, compared to its average volume of 504,529. The firm has a 50-day moving average price of $3.67 and a 200 day moving average price of $3.25. The firm has a market capitalization of $302.87 million, a PE ratio of -8.95 and a beta of 0.87. Trevi Therapeutics has a 52-week low of $1.35 and a 52-week high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the firm earned ($0.08) EPS. Equities analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares in the last quarter. Hsbc Holdings PLC bought a new position in Trevi Therapeutics in the second quarter worth approximately $61,000. Intech Investment Management LLC bought a new stake in Trevi Therapeutics during the 3rd quarter valued at $63,000. China Universal Asset Management Co. Ltd. bought a new stake in Trevi Therapeutics during the 4th quarter valued at $67,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after buying an additional 11,450 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.